OLEMA PHARMACEUTICALS INC. - COMMON STOCK

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 8 2024 15:30:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 7 2024 15:29:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 6 2024 15:28:00 提供 Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in June

28 5 2024 06:03:00 提供 Nasdaq GlobeNewswire

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

15 5 2024 06:01:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

08 5 2024 15:02:00 提供 Nasdaq GlobeNewswire

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

08 5 2024 06:02:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 5 2024 15:37:00 提供 Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in May

01 5 2024 06:02:00 提供 Nasdaq GlobeNewswire

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

08 4 2024 15:30:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 4 2024 15:29:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

11 3 2024 15:03:00 提供 Nasdaq GlobeNewswire

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

06 3 2024 06:03:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 3 2024 15:30:00 提供 Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 2 2024 06:01:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 2 2024 15:30:00 提供 Nasdaq GlobeNewswire

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

08 1 2024 07:12:48 提供 Nasdaq GlobeNewswire

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 1 2024 15:01:00 提供 Nasdaq GlobeNewswire

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

05 12 2023 11:27:48 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 12 2023 15:29:00 提供 Nasdaq GlobeNewswire